Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angus G Dalgleish

Showing results (11-20 of 83) with videos related to

Pageof 9
Sort By:
Advances in Cancer Research|December 6, 2008
HIV induced AIDS and related cancers: chronic immune activation and future therapeutic strategiesMartin Cadogan, Angus G Dalgleish
The Lancet. Infectious Diseases|September 27, 2008
HIV immunopathogenesis and strategies for interventionMartin Cadogan, Angus G Dalgleish
Cancer Chemotherapy and Pharmacology|June 16, 2009
MTT assays can underestimate cell numbersWai M Liu, Angus G Dalgleish
Future Oncology (London, England)|July 27, 2012
Cancer cell-derived supernatants that support the carcinogenic process: a future cancer therapy target?Wai M Liu, Angus G Dalgleish
Therapeutic Advances in Vaccines and Immunotherapy|January 10, 2019
The failure of radical treatments to cure cancer: can less deliver more?Angus G Dalgleish, Peter L Stern
Seminars in Oncology|May 19, 2012
The potential beneficial effects of drugs on the immune response to vaccinationWai M Liu, Angus G Dalgleish
Advances in Cancer Research|March 9, 2002
Chronic immune activation and inflammation in the pathogenesis of AIDS and cancerAngus G Dalgleish, Ken J O'Byrne
Oncology Letters|June 28, 2022
The role of immune modulation and anti-inflammatory agents in the management of prostate cancer: A case report of six patientsAngus G Dalgleish, Wai M Liu
Expert Review of Anticancer Therapy|February 2, 2022
Naltrexone at low doses (LDN) and its relevance to cancer therapyWai M Liu, Angus G Dalgleish
Journal of Translational Medicine|August 16, 2018
Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicityAngus G Dalgleish, Satvinder Mudan, Alberto Fusi
Pageof 9

Showing results (11-20 of 83) with videos related to

Sort By:
Pageof 9
Advances in Cancer Research|December 6, 2008
HIV induced AIDS and related cancers: chronic immune activation and future therapeutic strategiesMartin Cadogan, Angus G Dalgleish
The Lancet. Infectious Diseases|September 27, 2008
HIV immunopathogenesis and strategies for interventionMartin Cadogan, Angus G Dalgleish
Cancer Chemotherapy and Pharmacology|June 16, 2009
MTT assays can underestimate cell numbersWai M Liu, Angus G Dalgleish
Future Oncology (London, England)|July 27, 2012
Cancer cell-derived supernatants that support the carcinogenic process: a future cancer therapy target?Wai M Liu, Angus G Dalgleish
Therapeutic Advances in Vaccines and Immunotherapy|January 10, 2019
The failure of radical treatments to cure cancer: can less deliver more?Angus G Dalgleish, Peter L Stern
Seminars in Oncology|May 19, 2012
The potential beneficial effects of drugs on the immune response to vaccinationWai M Liu, Angus G Dalgleish
Advances in Cancer Research|March 9, 2002
Chronic immune activation and inflammation in the pathogenesis of AIDS and cancerAngus G Dalgleish, Ken J O'Byrne
Oncology Letters|June 28, 2022
The role of immune modulation and anti-inflammatory agents in the management of prostate cancer: A case report of six patientsAngus G Dalgleish, Wai M Liu
Expert Review of Anticancer Therapy|February 2, 2022
Naltrexone at low doses (LDN) and its relevance to cancer therapyWai M Liu, Angus G Dalgleish
Journal of Translational Medicine|August 16, 2018
Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicityAngus G Dalgleish, Satvinder Mudan, Alberto Fusi
Pageof 9